Zveik O - Search Results

1

Subclinical imaging activity in multiple sclerosis patients during war-related psychological stress.

Zveik O, Friedman-Korn T, Rechtman A, Ganz T, Hoichman G, Shweiki L, Ekstein D, Vaknin-Dembinsky A. Zveik O, et al. Ann Clin Transl Neurol. 2025 Jan;12(1):17-25. doi: 10.1002/acn3.52241. Epub 2024 Nov 6. Ann Clin Transl Neurol. 2025. PMID: 39504253 Free PMC article.

2

Correction to: Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.

Rechtman A, Friedman-Korn T, Zveik O, Shweiki L, Hoichman G, Vaknin-Dembinsky A. Rechtman A, et al. Among authors: zveik o. J Neurol. 2024 Oct;271(10):7065. doi: 10.1007/s00415-024-12550-7. J Neurol. 2024. PMID: 39231860 Free PMC article. No abstract available.

3

Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model.

Ganz T, Fainstein N, Theotokis P, Elgavish S, Vardi-Yaakov O, Lachish M, Sofer L, Zveik O, Grigoriadis N, Ben-Hur T. Ganz T, et al. Among authors: zveik o. Brain Behav Immun. 2024 Nov;122:497-509. doi: 10.1016/j.bbi.2024.08.032. Epub 2024 Aug 22. Brain Behav Immun. 2024. PMID: 39179123 Free article.

4

The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells.

Zveik O, Rechtman A, Ganz T, Vaknin-Dembinsky A. Zveik O, et al. Mol Neurodegener. 2024 Jul 12;19(1):53. doi: 10.1186/s13024-024-00742-8. Mol Neurodegener. 2024. PMID: 38997755 Free PMC article. Review.

5

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.

Rechtman A, Freidman-Korn T, Zveik O, Shweiki L, Hoichman G, Vaknin-Dembinsky A. Rechtman A, et al. Among authors: zveik o. J Neurol. 2024 Aug;271(8):5102-5108. doi: 10.1007/s00415-024-12438-6. Epub 2024 May 29. J Neurol. 2024. PMID: 38809270 Free PMC article.

6

A protective effect of lower MHC-II expression in MOGAD.

Rechtman A, Zveik O, Haham N, Brill L, Vaknin-Dembinsky A. Rechtman A, et al. Among authors: zveik o. J Neuroimmunol. 2024 Jun 15;391:578351. doi: 10.1016/j.jneuroim.2024.578351. Epub 2024 Apr 26. J Neuroimmunol. 2024. PMID: 38703720

7

Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.

Haham N, Zveik O, Rechtman A, Brill L, Vaknin-Dembinsky A. Haham N, et al. Among authors: zveik o. J Neuroimmunol. 2024 Mar 15;388:578289. doi: 10.1016/j.jneuroim.2024.578289. Epub 2024 Jan 17. J Neuroimmunol. 2024. PMID: 38301597

8

Anti- and pro-inflammatory milieu differentially regulate differentiation and immune functions of oligodendrocyte progenitor cells.

Zveik O, Rechtman A, Brill L, Vaknin-Dembinsky A. Zveik O, et al. Immunology. 2024 Apr;171(4):618-633. doi: 10.1111/imm.13757. Epub 2024 Jan 19. Immunology. 2024. PMID: 38243672

9

Thyroid hormone dysfunction in MOGAD and other demyelinating diseases.

Rechtman A, Zveik O, Haham N, Freidman-Korn T, Vaknin-Dembinsky A. Rechtman A, et al. Among authors: zveik o. J Neurol Sci. 2024 Feb 15;457:122866. doi: 10.1016/j.jns.2024.122866. Epub 2024 Jan 3. J Neurol Sci. 2024. PMID: 38242048

10

Oligodendrocyte progenitor cells differentiation induction with MAPK/ERK inhibitor fails to support repair processes in the chronically demyelinated CNS.

Ganz T, Zveik O, Fainstein N, Lachish M, Rechtman A, Sofer L, Brill L, Ben-Hur T, Vaknin-Dembinsky A. Ganz T, et al. Among authors: zveik o. Glia. 2023 Dec;71(12):2815-2831. doi: 10.1002/glia.24453. Epub 2023 Aug 23. Glia. 2023. PMID: 37610097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters